Connecticut's final medical-only cannabis dispensary, Bluepoint Wellness, plans to relocate within Westport after repeated rejections of its recreational sales bid. The move signals the potential end of standalone medical marijuana outlets in the state, as zoning barriers force a pivot toward hybrid operations in a new town. Opened in late 2019, Bluepoint has operated apart from the 61 licensed stores, 29 of which now sell both medical and recreational products.
Zoning Rejections Block Westport Expansion
Westport's Planning and Zoning Commission has denied Bluepoint's requests to sell recreational cannabis, citing traffic concerns after the town amended its zoning code in 2021 to prohibit such businesses following statewide adult-use legalization. Bluepoint co-founder Nick Tamborrino highlighted the frustration in 2023 testimony, noting daily turnaways of local residents seeking recreational products. In response, the company launched Venu Flower Collective, a recreational store 50 miles away in Middletown, while shifting its medical operations to a temporary Westport site for 18 to 24 months before a full move.
Medical Patient Decline Accelerates Hybrid Trend
Recreational sales launched in 2023 have slashed medical cannabis patients from nearly 49,000 to under 32,000. Annual medical sales fell $21 million in 2025, with transactions dropping from 2.6 million in 2024 to 2.2 million. Fine Fettle chief operating officer Ben Zachs observed that sustaining medical-only models grows harder amid these shifts. State cannabis ombudsman Erin Gorman Kirk points to high prices, inconsistent quality, and limited variety—especially versus neighbors like Massachusetts and Rhode Island—as key drivers.
End of an Era Reshapes Access Landscape
Without Westport zoning updates, Bluepoint's relocation could eliminate Connecticut's medical-only dispensaries entirely, pushing all outlets toward hybrids that blend patient and adult-use sales. This evolution mirrors national patterns where recreational markets overshadow medical ones, prioritizing broader access over specialized care. Patients may face adjusted pricing and selection, while operators adapt to consolidate under unified models, reflecting policy tensions between local control and state-level cannabis expansion.
